Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Aurora Cannabis’ Cost Per Gram of Medical cannabis from Q3 2017 onwards. This includes cash cost of production and sales per gram.
Both of these metrics are non-IFRS, which uses non-standardized methods and may differ from company to company. Aurora Cannabis’ cash cost of sales is generally calculated by the total cost of sales as per IFRS and deducting the fair values of biological assets, non-cash production cost, any purchase from other licensed producers and cost of sales from service revenue, which is to be divided by the number of grams produced in the period. Whereas cash cost to produce is post-production cost, which can be derived easily by deducting packaging cost from the cash cost of sales. The reported figures may vary from company to company.
This is extremely important metric in the cannabis industry as it helps investors to understand which producer, among all, has a cost advantage. This, in turn, allows us to assess the competitiveness and profitability of licensed cannabis producers.
The year has recorded the highest revenue in Q4 of $5.9 million, up by 15% from Q3 2017, including the sale of 7,55,059 grams of cannabis. The company saw continued patient growth as well as revenue growth since the launch of commercial operations in January 2016. Acquisition of Peloton pharmaceuticals and additional investment in constructing new production facility in Alberta and Quebec cities helped the company to increase the production capacity, which in turn increased the revenue and made the company to reduce the cash cost of sales and maintain the same cash cost to produce for Q3 and Q4.
Aurora strengthened its financial and liquidity position during the third quarter with $3,56,266 by issuing debentures and warrants. The company continued to grow its aggressive business and operating strategies that include major domestic and international expansion projects. With the acquisition of CanniMed facilities and lower utility costs in summer months, the cash cost of sales and cash cost to produce increased by $0.7 and $1.7 in Q4, respectively. The company also invested heavily in Sky Class facility around $120 million, with a view that it will reduce the cost of producing a gram of cannabis to $1 per gram.
Due to the increased production volume and higher plant yield, the company spotted a drop-in cash cost to produce to $1.14 per gram in Q4, down by 19.7% from the previous quarter. Because of the new regulatory requirements under the cannabis act, the company faced an increase in packaging costs, which leads to the higher differences between cash cost to produce and cash cost of sales during the year.
Cash cost to produce decreased to $0.85 per gram, down by 25% from the previous quarter, merely because of the hike in the production volume by 43%. But the case is opposite in Q2; it saw a decrease in production volume by 26% to 30,691 kilograms resulting in low absorption of overheads. Cash cost to produced also increased to $0.88 gram, up by 4% from $0.03 in Q1 2020.
Did you like Aurora Cannabis’ Cost Per Gram of Medical cannabis statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.